Adamax Research Overview (also known as N-Acetyl Semax Amide, Adamax peptide)
A next-generation synthetic nootropic peptide derived from the same ACTH-based backbone as Semax, modified with an N-terminal acetyl group and C-terminal adamantane moiety to improve blood-brain barrier penetration, bioavailability, and half-life. Studied for cognitive enhancement, neuroprotection, memory consolidation, and executive function support.
For broader research context on nootropic compounds, including comparative stacks, cycling considerations, and interaction notes, see the Complete Nootropic Cheat Sheet.
What Is Adamax?
Adamax is a synthetic nootropic peptide analog developed in Russia at the same research institutions responsible for Semax and Selank. It belongs to the class of ACTH/MSH-derived peptides and is structurally related to Semax, sharing the core Pro-Gly-Pro tripeptide sequence that confers much of its neuroprotective activity.
Mechanism of Action
Like other melanocortin peptide analogs, Adamax interacts with melanocortin receptors and modulates BDNF expression in key brain regions including the hippocampus and prefrontal cortex. It also demonstrates anti-inflammatory properties in the CNS by reducing expression of pro-inflammatory cytokines in neural tissue.
Research Applications
Adamax has been studied for cognitive enhancement, neuroprotection against ischemic injury, anxiolytic effects, and stress resilience. Animal studies show improved performance on memory and learning tasks, reduced anxiety-like behavior, and protection against hippocampal damage in models of ischemia. It is typically administered intranasally like Semax, as this route maximizes CNS delivery while minimizing peripheral enzymatic degradation.
Quick Reference
| Literature-Reported Dose Range | 200-300 mcg |
| Literature-Reported Frequency | 1x daily |
| Literature-Reported Cycle Length | 2-4 weeks |
| Literature-Reported Washout | 2-4 weeks |
| Storage | Fridge 2-8°C, 14-30 days |
| Sites Reported in Studies | Belly, thigh, arm |
| Timing | Morning preferred |
Research Indications
Cognitive
Cognitive Enhancement
Preliminary research and anecdotal reports suggest improvements in focus, mental clarity, memory, and ability to handle complex cognitive tasks.
Neuroplasticity Support
BDNF upregulation promotes formation of new neural connections and synaptic plasticity for long-term cognitive improvements.
Learning and Memory
May enhance memory formation, information retention, and learning efficiency through hippocampal BDNF-TrkB pathway activation.
Neuroprotective
Stroke Recovery
Preliminary observations indicate improved neurological outcomes when administered shortly after stroke through oxidative stress reduction.
Oxidative Stress Protection
Demonstrates antioxidant properties protecting neurons from oxidative damage and inflammation-induced injury.
Neuronal Maintenance
Supports neuronal survival, growth, and maintenance through BDNF enhancement and microtubule stabilization.
Mood
Mood Enhancement
Influences serotonin and dopamine levels to elevate mood, reduce depressive symptoms, and improve emotional resilience.
Anxiety Reduction
Anecdotal reports indicate reduced feelings of overwhelm and anxiety through balanced neurotransmitter activity.
Stress Resilience
May help regulate stress hormones via HPA axis modulation, improving stress response and mood stability.
Research Protocols
As reported in cited literature and research-community logs (see Research Citations below) — not a personal dosing recommendation.
| Research Application | Dose | Frequency | Route |
|---|
| Cognitive enhancement | 200-300mcg | 1x daily | SubQ or Nasal |
| Neuroprotection | 300mcg | 1-2x daily | SubQ |
| Mood support | 200mcg | 1x daily (morning) | SubQ or Oral |
| Initial trial | 100-200mcg | 1x daily | SubQ |
Timing
Recommended administration window: morning preferred. Typical onset: hours for acute, 2-4 weeks for neuroplasticity.
Peptide Interactions
Adamax is an enhanced derivative of Semax with improved stability and bioavailability
Adamax incorporates adamantyl portion from P21, may complement cognitive benefits
Different mechanisms - Adamax targets neurological function, BPC-157 focuses on tissue repair
Both enhance cognition through different primary mechanisms (Adamax: melanocortin/BDNF, Noopept: glutamate receptors/NGF) but share BDNF upregulation. May have additive benefits - start with lower doses and monitor for overstimulation.
Reported Research Timeline
01Hours 1–4 (reported in cited studies): potential acute cognitive enhancement
02Week 1–2 (reported in cited studies): enhanced mental clarity, mood improvements
03Week 2–4 (reported in cited studies): neuroplasticity benefits, sustained cognitive gains
04May experience headaches or anxiety at higher doses
Note: Effects highly individual, primarily anecdotal
Safety Notes
Included for harm-reduction awareness only, in the event this compound is encountered outside its labeled research use. Inclusion here does not imply RUO Codes endorses, recommends, or instructs human use.
CRITICAL: Experimental peptide with very limited human research data
Use sterile injection technique
Start with lower doses to assess tolerance
Monitor for cardiovascular effects (blood pressure, palpitations)
Cycle with breaks to prevent tolerance
Not recommended during pregnancy or breastfeeding
Consult healthcare provider before use
Seek Medical Attention If:
Persistent or severe headaches
Cardiovascular symptoms (chest pain, palpitations)
Severe anxiety, insomnia, or mood changes
Unusual neurological symptoms
Persistent injection site reactions
Any concerning symptoms - consult provider immediately
Quality Indicators
Verified Marker
White, Fluffy Powder
Lyophilized Adamax should appear as white to off-white, fluffy powder filling the vial bottom.
Verified Marker
Clear Solution After Reconstitution
When properly mixed with BAC water, solution should be crystal clear with no particles or cloudiness.
Acceptable Range
Slight Compaction
Minor compaction from shipping is acceptable if powder dissolves completely with gentle swirling.
Quality Concern
Discoloration
Any yellow, brown, or unusual coloration indicates oxidation or degradation. Should be white to off-white only.
Quality Concern
Cloudy After Reconstitution
Persistent cloudiness or particles after mixing indicate degraded or contaminated peptide.
Research Citations
- Adamax: A Novel Semax Derivative with Enhanced Nootropic Properties
Various Researchers, 2024-2025, Peptide Research Compilations - Adamax & P21: Two New Nootropic Peptides To Watch Closely
Campbell, J., 2024, Jay Campbell Research - The Regulatory Peptide Semax: Nootropic and Neuroprotective Effects (Parent Compound)
Ashmarin, I.P., et al., 1997, Russian Journal of Genetics - Peptide Semax Affects the Expression of Genes Related to Immune and Vascular Systems in Rat Brain Ischemia (Parent Compound)
Medvedeva, E.V., et al., 2014, BMC Genomics - Rapid Elevation of BDNF Expression Following Semax Administration (Parent Compound)
Shadrina, M.I., Dolotov, O.V., et al., 2010, Doklady Biochemistry and Biophysics
Research Focus
Neuroprotection, Cognitive enhancement, Anxiety, Stress resilience, BDNF modulation
Verified Vendors Carrying Adamax
Frequently Asked Questions
What should researchers watch for with Adamax?
Included for harm-reduction awareness only, in the event this compound is encountered outside its labeled research use. Inclusion here does not imply RUO Codes endorses, recommends, or instructs human use.
What should researchers expect over time with Adamax?
Hours 1–4 (reported in cited studies): potential acute cognitive enhancement
How is Adamax typically administered in research?
As reported in cited literature and research-community logs (see Research Citations below) — not a personal dosing recommendation.
Browse all peptides in the Encyclopedia →